Senna Plus

Quick links to important sections

Senna Plus

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Senna Plus

Property Description
Active ingredient Docusate Sodium and Sennosides
Form Oral tablet, capsule, or solution
Pharmacological class Stimulant and Emollient Laxative
Common use Symptomatic relief of difficulty passing stool
Origin Semi-synthetic (Synthetic Docusate, Botanical Senna)

What Type of Medicine is Senna Plus?

Senna Plus is an oral fixed-dose combination preparation that is widely classified as a Stimulant and Emollient Laxative. It is available for oral administration as a non-prescription oral tablet or capsule. This formulation is clinically recognized for addressing constipation by targeting both the consistency and motility issues involved, differentiating it from single-agent therapies. Similar formulations are commonly sold under trade names like Senokot S and Peri-Colace, establishing Senna Plus as a standardized therapeutic category.

Composition and Dual-Action Approach

The composition of Senna Plus is defined by two key active ingredients: Sennosides and Docusate Sodium. The Sennosides, derived from the botanical source Senna, function as the stimulant component, which is recognized for enhancing propulsive bowel motility. Conversely, Docusate Sodium is a synthetic compound categorized as a stool softener and surfactant agent, chemically designed to condition the fecal matter. This combined formulation is strategically positioned for patients who require comprehensive support for regulating their bowel function.

General Purpose: Addressing Consistency and Motility

The general purpose of Senna Plus is to provide comprehensive, symptomatic relief for constipation by utilizing a synergistic effect. This dual-action treatment is often employed in scenarios such as managing bowel irregularity associated with certain medications or physical inactivity. It operates by softening the hardened stool mass through the emollient action while simultaneously enhancing the colon's propulsive movement, or peristalsis, through the stimulant action. This approach targets both the consistency and the movement required for a satisfactory and comfortable evacuation.

What side effects are possible with Senna Plus?

Possible Side Effects and Safety Information

The official safety information for Senna Plus (Sennosides and Docusate Sodium) is primarily organized around adverse effects in the gastrointestinal system and specific constraints on exposure duration. Regulatory documents list possible adverse reactions that include stomach cramps, abdominal pain, nausea, and diarrhea. These effects are typically associated with the medicine's stimulant action.


Documented Adverse Reactions and Safety Constraints

Category Documented Effects or Constraints
System-Organ Classes Primarily Gastrointestinal disorders; also Skin and subcutaneous tissue disorders (rash) and Renal and urinary disorders (harmless urine discoloration).
Serious Indicators Rectal bleeding or failure to have a bowel movement after use are defined in regulatory labeling as signs that may indicate a serious underlying condition. Severe fluid and electrolyte imbalance is also documented, particularly with excessive or long-term use.
Duration Limitation Regulatory labeling restricts use to providing short-term relief only. The product should not be used for more than one week as extended exposure is associated with a potential for dependency and electrolyte abnormalities.
Specific Restrictions The product is restricted in the presence of existing symptoms such as stomach pain, nausea, or vomiting. Use is also restricted when the patient is taking mineral oil.
Population Notes Use in children under 2 years of age requires specific consultation.

Regulatory Safety Structure

The medicine is structured by regulatory bodies as a short-term intervention, with its safety profile defined by explicit limitations on duration and use under specific pre-existing conditions. These documented constraints emphasize the product's function as a temporary solution and not a treatment for chronic conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Taking more than the recommended dose of Senna Plus (a combination of sennosides and docusate sodium) can lead to an overdose, primarily manifesting as severe gastrointestinal symptoms due to the excessive laxative effects.

Symptoms of Overdose

Overdose symptoms are mainly related to excessive fluid and electrolyte loss and may include:

  • Severe, persistent diarrhea, nausea, or vomiting
  • Intense abdominal pain and cramping
  • Dehydration (signs include extreme thirst, dry mouth, or decreased urination)
  • Electrolyte imbalance (which can lead to muscle weakness, irregular heartbeat, or dizziness)
  • Bloody stools

When to Seek Immediate Medical Attention

Immediate medical help is required if a suspected overdose occurs or if any of the following serious symptoms develop while taking the medication:

  • Rectal bleeding
  • Severe and unrelieved stomach pain, nausea, or vomiting
  • Signs of severe dehydration or electrolyte imbalance (e.g., fainting, confusion, irregular heartbeat, or seizure)
  • Failure to have a bowel movement after using the laxative, as this may indicate a more serious underlying condition.

In the event of a suspected overdose, contact your local emergency services or a poison control center right away. Do not induce vomiting unless specifically instructed to do so by a healthcare professional. Prolonged and excessive use of laxatives, even without an acute overdose, can lead to chronic electrolyte imbalances and dependence.

Therapeutic Uses of Senna Plus

What Senna Plus Treats: Main Uses and Benefits

Senna Plus is generally used to provide short-term symptomatic relief for occasional constipation and acute bowel irregularity. It is a combination product relevant in contexts involving distressing symptoms of difficulty passing stool.

Dual-Action Relief for Hard Stool and Sluggish Movement

The medication is specifically applied when patients experience both a hardened, dry stool mass and sluggish bowel movement (slow movement). This combination may assist with general well-being and supports easing the symptoms of difficult passage. This dual-action generally supports patients during episodes of heightened discomfort.

Support for High-Need Clinical Scenarios

This therapy is considered relevant in settings where the goal is to manage the need for reduced physical strain during bowel movements, such as during post-operative recovery or when managing painful conditions like hemorrhoids. It is commonly used to provide supportive relief for medication-induced constipation and supports the patient during difficult episodes by easing distress during periods of limited mobility.


Quick Fact: Relief for Dual Symptoms

The formulation is applied to address two key symptomatic domains: fecal consistency (stool hardness) and bowel motility (sluggish movement) when supportive relief is needed.

Regulatory References

  1. DailyMed label information for Senna and Docusate Sodium

Eligibility and Restrictions for Use

Senna Plus (a combination of docusate sodium and sennosides) is generally used to relieve occasional constipation in adults and children typically 2 years of age and older. Dosing for children under the age of 12 should be guided by a healthcare professional.


Contraindications

This medication is not safe for everyone. Senna Plus should not be used by individuals with certain pre-existing conditions or circumstances, including:

  • Known allergy or hypersensitivity to senna, sennosides, docusate, or any other ingredients.
  • Symptoms of appendicitis, undiagnosed abdominal pain, nausea, or vomiting.
  • Intestinal obstruction, perforation, or fecal impaction.
  • Gastrointestinal bleeding or rectal bleeding.
  • Inflammatory Bowel Diseases, such as ulcerative colitis or Crohn's disease.

Important Usage Cautions

Consult with a healthcare provider before use if you are pregnant or breastfeeding, have kidney or heart problems, or have experienced a sudden change in bowel habits lasting longer than two weeks. Do not use Senna Plus for more than one week without medical direction, as prolonged use can lead to laxative dependence and electrolyte imbalance. Do not take this product if you are concurrently taking mineral oil.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Senna Plus details several important interactions that may affect the safety or effectiveness of concurrent medications. These interactions are categorized based on their resulting clinical requirement.

Restricted and Contraindicated Combinations

  • Mineral Oil (Liquid Paraffin): Concomitant use is restricted due to the docusate component, which may enhance the systemic absorption of mineral oil.
  • Sulfate-Containing Bowel Preparations (e.g., Sodium/Potassium/Magnesium Sulfate): Co-administration with other strong laxative or bowel cleansing preparations may increase the risk of serious local gastrointestinal injury, such as mucosal ulceration or ischemic colitis.

Interactions Affecting Electrolyte Balance

  • Cardiac Glycosides (e.g., Digoxin): The risk of serious toxicity from cardiac glycosides is increased if the patient develops hypokalemia (low potassium levels), which can be a potential effect of the senna component, especially with prolonged use.
  • Other Hypokalemia-Inducing Agents (e.g., Diuretics, Corticosteroids): Concurrent use with medications known to induce potassium depletion may result in a greater imbalance of salts and minerals, requiring caution and monitoring.

Timing-Based Administration Requirement

To ensure the full desired effect of other medications, this product should not be taken within two hours of any other medicine. This separation rule is intended to minimize interference with the absorption or action of other administered drugs.

Mechanism of Action

The mechanism of action for this combination product involves two complementary and distinct pharmacodynamic domains that modulate the physical and motile properties of the lower intestine. The dual action modulates both the consistency of the fecal mass and the propulsive movement of the colon simultaneously.

Enhanced Propulsive Motility and Fluid Secretion

This mechanism is driven by the Sennosides component. Their active metabolites directly stimulate the enteric nervous system (ENS) in the colon and inhibit the reabsorption of water and electrolytes across the epithelial cells. This dual effect results in increased coordinated peristaltic contractions and a net increase in the fluid volume within the colonic lumen.

Physicochemical Conditioning and Stool Softening

The Docusate Sodium component exerts its effect through a surfactant action that targets the contents of the colon. By reducing the surface tension between the water and lipid components in the fecal mass, Docusate allows for the efficient incorporation of water into the stool. This process of fecal conditioning increases the softness and bulk of the intestinal contents, which modulates the mechanical resistance during transit.

Dosage and Administration Information

Official Administration Guidelines for Senna Plus

The administration of Senna Plus, a fixed-dose combination of docusate sodium (50 mg) and sennosides (8.6 mg), follows a standardized oral protocol. This product is intended for short-term use and should not be used for a period exceeding seven days unless under the explicit direction of a health professional.


Standardized Dosing Regimens

Dosing is determined by age, with the product taken as a single dose or in divided doses, preferably at bedtime due to the typical action window of 6 to 12 hours. Use for children under two years of age must be determined by a doctor.

Age Group Starting Dose Maximum Daily Dose (Total)
Adults and Children 12+ 2 tablets once daily 8 tablets (4 tablets twice daily)
Children 6 to under 12 1 tablet once daily 4 tablets (2 tablets twice daily)
Children 2 to under 6 1/2 tablet once daily 2 tablets (1 tablet twice daily)

Procedural Requirements

The official protocol dictates that each dose should be administered with a full glass of water (approximately 8 ounces) to facilitate the proper intake of the solid oral dosage form. If a dose is missed, it is advised to skip the missed dose if the time for the next scheduled dose is near; doses must not be doubled to compensate. This structure ensures a precise, temporally constrained, and age-appropriate method of use, adhering strictly to the documented instructions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Senna Plus

Evidence for Use in General Constipation Management

The combination of sennosides and docusate has been studied in research that evaluated symptoms in adults with occasional or chronic constipation. Studies have typically been designed as short-term Randomized Controlled Trials (RCTs), where researchers monitored outcomes related to functional imbalance, such as the time elapsed to a first bowel movement and the frequency of bowel movements per week. Studies reported measurements of bowel movement frequency that were observed to be higher compared to initial baseline levels during the study period. Findings were mixed in trials comparing the combination product directly against its single components (sennosides or docusate) for most measured outcomes.

Evidence for Use in Opioid-Induced Constipation (OIC)

The combination was evaluated in research concerning the management of constipation in patients receiving opioid therapy. Studies conducted during periods where symptoms become more noticeable have primarily been short-term RCTs. The outcomes measured were centered on spontaneous bowel movements (SBMs). Studies reported SBM frequency measurements that were observed to be higher in the combination group compared to placebo over the defined time intervals. Reported outcomes were short-term, providing measured data on symptoms.

Long-Term Studies and Follow-Up Data

Most evidence is derived from studies exploring short-term symptom changes. Long-term effects are not fully established because research examining continuous use or follow-up beyond a few months is scarce. There is limited information for long-term outcomes that reflect whether the observed patterns are maintained over extended periods.

Evidence in Special Populations

Research examined certain specific patient groups, such as the geriatric population (older adults). Data for certain groups remain limited. For instance, there are few dedicated studies that have specifically evaluated the use of the combination product in pediatric patients or in pregnant populations. Therefore, the results apply only to the populations studied, and findings for these specific subgroups are often uncertain due to small sample sizes or lack of dedicated research.

What is Still Uncertain About Senna Plus Research

One major limitation is that comparative evidence is lacking against many modern prescription or over-the-counter laxatives. Furthermore, evidence quality varies across studies, due to differences in how constipation was defined and the patient populations included. Long-term effects are not fully established, as follow-up durations were limited in most key trials. Research exploring the product in patients with multiple concurrent health conditions is generally insufficient, meaning the results apply only to the populations studied and may not fully reflect real-world diversity.

Key Studies & References

  1. How useful is docusate in patients at risk for constipation: a systematic review of the evidence in the chronically ill
  2. Senna and Docusate Sodium Film Coated Red Tablets 8.6 mg/ 50 mg Laxative - DailyMed (FDA Monograph)

Frequently Asked Questions (FAQ)

Common questions about Senna Plus (FAQ)


Q: What is the difference between Senna Plus and plain Senna?

Senna Plus is formally defined as a combination product because it contains two distinct active ingredients. Official product information describes the combination as including both sennosides (a stimulant laxative) and docusate sodium (a stool softener). Plain Senna products typically contain only the sennosides laxative component.


Q: How quickly is Senna Plus expected to work?

Official regulatory labels indicate that the product is generally expected to produce a bowel movement within a timeframe of 6 to 12 hours after it is taken. This time frame reflects the expected window of effect. The guidance suggests taking the product before bedtime to align with the typical onset time.


Q: Does Senna Plus interact with common pain relievers?

Regulatory documents list specific drug interactions, such as an important warning concerning mineral oil. The official warnings focus on specific restricted combinations and do not generally list common non-prescription pain relievers.


Q: What is the typical timeframe for a first bowel movement after taking Senna Plus?

Official product information states that the product generally produces an effect (a bowel movement) within the range of 6 to 12 hours. This timeframe is provided in official information to describe the product's typical action window.


Q: What happens if a dose of Senna Plus is missed?

Regulatory guidance describes skipping the missed dose if the time for the next scheduled dose is near. Product instructions emphasize that the dose must not be doubled in an attempt to make up for the missed one.


Q: Is Senna Plus available in different forms, such as liquid or tablet?

Official product information shows that this medication is available for oral use in several different forms. Depending on the manufacturer, these include tablets, capsules, and softgels.


Q: What does official drug information say about the ingredients in Senna Plus?

The official label specifies that the product contains two active ingredients: the stimulant laxative sennosides 8.6 mg and the stool softener docusate sodium 50 mg. These amounts define the strength of the combination product.


Q: What is the general duration of effect for a single dose of Senna Plus?

Official documents define the action time frame for the product. A single dose is expected to lead to a result (a bowel movement) within 6 to 12 hours.


Q: Do you always need a prescription for Senna Plus?

According to regulatory classification, Senna Plus is formally categorized as an Over-The-Counter (OTC) drug. This means the product is generally available for purchase without a prescription.


Q: Is Senna Plus considered safe for elderly patients?

Regulatory guidance suggests that individuals who are 65 years of age and older should consult with a health professional before using the product. Regulatory documents indicate that long-term or excessive use is generally not recommended for older adults.


Q: Is it possible to become dependent on Senna Plus?

The official warning states that frequent or continued use of stimulant laxatives has been associated with the bowels becoming dependent on laxatives. This is the main reason regulatory documents limit the duration of use to short-term relief only.


Q: Do official drug labels mention dehydration as a possible issue with Senna Plus?

While the term 'dehydration' is not always explicitly used, the official warnings state that excessive or prolonged use can lead to severe fluid and electrolyte imbalance. This documented condition is associated with fluid loss and electrolyte imbalance.


Q: Can children or adolescents use Senna Plus?

Official regulatory labels provide specific directions and dosing instructions for different pediatric age groups, including children aged 12 years and older, children 6 to under 12 years, and children 2 to under 6 years. Use for children under 2 years of age requires specific consultation with a doctor.


Q: What is the role of the stool softener component in Senna Plus?

The stool softener, docusate sodium, is categorized as a surfactant. Its role is to help water effectively mix into the fecal mass, which aids in softening the stool to allow for easier transit.


Q: What kind of research evidence exists for Senna Plus in specific patient groups?

Official information and studies indicate that research has examined the product's use for general occasional constipation in adults. Some research has also specifically looked at effects in geriatric populations and for managing symptoms of opioid-induced constipation.


Q: What does official guidance say about discontinuing Senna Plus use?

Regulatory guidance advises stopping use and asking a health professional if specific serious symptoms occur. These include any signs of rectal bleeding or if the patient fails to have a bowel movement after using the laxative, as these may indicate a serious underlying condition.


Q: Is Senna Plus known to cause any discoloration of the intestinal lining?

This condition, known as melanosis coli, has been documented in scientific literature and is typically associated with long-term use of sennosides. It is characterized by a harmless brown pigmentation of the colon lining.


Q: What is the purpose of the dye or coloring used in some Senna Plus tablets?

The official drug label lists the dye or coloring, such as FD&C Yellow No. 6, in the 'Inactive Ingredients' section. The purpose of these non-active components is for product identification and presentation.


Q: What is the consensus on Senna Plus use during breastfeeding, according to regulatory documents?

The official regulatory guidance asks that any individual who is breastfeeding must ask a health professional before use. The label requires individuals who are breastfeeding to consult a health professional before use.


Q: Why is it described as a 'stimulant' laxative?

It is described as a stimulant laxative because its sennosides component works by directly acting on the large intestine. This action increases the intestines' propulsive motility to achieve the laxative effect.


Q: Is it common for people to report that Senna Plus makes them feel nauseous?

The official drug label lists nausea as one of the potential adverse reactions that may occur with use. It is also listed as a symptom that regulatory guidance suggests consulting a health professional about before the product is used.


Q: Does the drug label for Senna Plus mention its use during pregnancy?

The regulatory guidance includes a specific warning for this condition. The regulatory guidance asks any individual who is pregnant to ask a health professional before use of the product.


Q: What is the significance of the 'Plus' ingredient in Senna Plus?

The 'Plus' is used to signify the addition of the stool softener (docusate sodium) to the base stimulant laxative (sennosides), creating a product with dual actions.


Q: Does Senna Plus cause changes in urine color?

Official product information and related literature indicate that the senna component may change urine color. This change is described as harmless and may result in a reddish or yellowish-brown hue.


Q: How does the time of day a person takes Senna Plus influence the expected results?

Because the product typically takes 6 to 12 hours to work, official directions suggest taking the product preferably at bedtime. Taking it at this time is intended to produce a bowel movement the following morning.


Q: Do product inserts specify how long to wait before seeking medical help if the drug hasn't worked?

The label advises stopping use and asking a doctor if the patient fails to have a bowel movement after taking the laxative. This is listed as a serious warning that may indicate an underlying condition.


Q: Is it true that Senna Plus is a combination product?

Yes, official regulatory classification defines Senna Plus as a fixed-dose combination product. This is because it contains a predetermined amount of both sennosides and docusate sodium.


Q: Is the onset of action different for the senna component versus the docusate component?

Official product information describes the intended combined product as producing a result within 6 to 12 hours. The overall effect is therefore viewed within a single, combined time frame for the dual-action medication.


Q: Can Senna Plus be used for something other than occasional constipation?

The official drug label specifies that the intended use of the product is to relieve occasional constipation (irregularity). The label does not mention or authorize other uses.

How should Senna Plus be stored and disposed of?

How to Store and Dispose of Senna Plus?

Senna Plus (Docusate Sodium and Sennosides) must be stored under specific conditions to maintain product quality.


Storage Conditions

Requirement Specific Instruction
Temperature Store at Controlled Room Temperature, typically 20°C to 25°C (68°F to 77°F), with excursions permitted up to 30°C.
Protection Store away from excess heat and moisture.
Container Keep in the original container and keep the container tightly closed. Do not use if the safety seal is broken.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Expired or unused medication must be properly discarded. The product should not be flushed down the toilet or poured into a drain unless instructed to do so. Consult a pharmacist or local waste disposal company for official guidance on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Senna Plus found in:

A-Z Index: